Biología molecular del cáncer

Conditional transgenic expression of PIM1 kinase in prostate induces inflammation-dependent neoplasia.

DNA methylation signatures identify biologically distinct thyroid cancer subtypes.

Identification of oxidative stress related proteins as biomarkers for lung cancer and chronic obstructive pulmonary disease in bronchoalveolar lavage.

Identification of proteomic signatures associated with lung cancer and COPD.

Inhibition of HSP90 molecular chaperones: moving into the clinic.

MAP17 and SGLT1 protein expression levels as prognostic markers for cervical tumor patient survival.

Markers of cellular senescence.

Oxidation of anticancer Pt(II) complexes with monodentate phosphane ligands: towards stable but active Pt(IV) prodrugs.

Proteomic biomarkers in lung cancer.

Spinophilin loss correlates with poor patient prognosis in advanced stages of colon carcinoma.

The PIM Family of Serine/Threonine Kinases in Cancer.

The second generation of iodido complexes: trans-[PtI2(amine)(amine')] bearing different aliphatic amines.

Association between the miRNA signatures in plasma and bronchoalveolar fluid in respiratory pathologies.

MAP17 and the double-edged sword of ROS.

MAP17, a ROS-dependent oncogene.

PDGFRα/β and VEGFR2 polymorphisms in colorectal cancer: incidence and implications in clinical outcome.

Pim kinases in cancer: diagnostic, prognostic and treatment opportunities.

Spinophilin: a new tumor suppressor at 17q21.

The essential role of PIM kinases in sarcoma growth and bone invasion.

p38α limits the contribution of MAP17 to cancer progression in breast tumors.

Cancer, senescence, and aging: translation from basic research to clinics.

Down-regulation of spinophilin in lung tumours contributes to tumourigenesis.

Epigenetic mechanisms in senescence, immortalisation and cancer.

Pim 1 kinase inhibitor ETP-45299 suppresses cellular proliferation and synergizes with PI3K inhibition.

Spinophilin acts as a tumor suppressor by regulating Rb phosphorylation.

Spinophilin loss contributes to tumorigenesis in vivo.

The preparation and characterization of trans-platinum(IV) complexes with unusually high cytotoxicity.

Between bench and bed side: PI3K inhibitors

Bypassing cellular senescence by genetic screening tools

Cellular senescence as a target in cancer control.

Exploring the gain of function contribution of AKT to mammary tumorigenesis in mouse models.

Human TRIB2 is a repressor of FOXO that contributes to the malignant phenotype of melanoma cells

Targeting of p53-transcriptional dysfunction by conditionally replicating adenovirus is not limited by p53-homologues.

The PKB/AKT pathway in cancer.

The TGF-beta co-receptor endoglin modulates the expression and transforming potential of H-Ras

The role of p53 in the cellular toxicity by active trans-platinum complexes containing isopropylamine and hydroxymethylpyridine.

Understanding FOXO, new views on old transcription factors.

Adding more content to screening: reactivation of FOXO as a therapeutic strategy.

Chemical interrogation of FOXO3a nuclear translocation identifies potent and selective inhibitors of phosphoinositide 3-kinases.

Cold-inducible RNA-binding protein bypasses replicative senescence in primary cells through extracellular signal-regulated kinase 1 and 2 activation.

Influence of amine ligands on the aquation and cytotoxicity of trans-diamine platinum(II) anticancer complexes.

Inhibiting PI3K as a therapeutic strategy against cancer.

Mouse models to decipher the PI3K signaling network in human cancer.

Novel inhibitors of the PI3K family.

Using cells devoid of RAS proteins as tools for drug discovery.

Using multiplexed regulation of luciferase activity and GFP translocation to screen for FOXO modulators.

Activation of phosphatidylinositol 3-kinase by membrane localization of p110alpha predisposes mammary glands to neoplastic transformation.

Battling cancer on many fronts. Meeting on New Battlefields in Human Cancer--Attacking in Many Fronts.

Cellular senescence bypass screen identifies new putative tumor suppressor genes.

Characterization of the p53 response to oncogene-induced senescence.

Influence of (hydroxymethyl)pyridine and pyridine-carboxylic acids, in trans-position to the isopropylamine and amine ligands, on the cytotoxicity of platinum complexes.

Loss-of-function genetic screening identifies a cluster of ribosomal proteins regulating p53 function.

S-adenosylhomocysteine hydrolase downregulation contributes to tumorigenesis.

The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications.

Expression of CYP3A4 as a predictor of response to chemotherapy in peripheral T-cell lymphomas.

Extreme sensitivity to Yondelis (Trabectedin, ET-743) in low passaged sarcoma cell lines correlates with mutated p53.

Genetic cooperation between p21Cip1 and INK4 inhibitors in cellular senescence and tumor suppression.

Levels of p27(kip1) determine Aplidin sensitivity.

MAP17 enhances the malignant behavior of tumor cells through ROS increase.

MAP17 inhibits Myc-induced apoptosis through PI3K/AKT pathway activation.

MAP17 overexpression is a common characteristic of carcinomas.

Mice expressing myrAKT1 in the mammary gland develop carcinogen-induced ER-positive mammary tumors that mimic human breast cancer.

Mst1, RanBP2 and eIF4G are new markers for in vivo PI3K activation in murine and human prostate.

New trans-platinum drugs with phosphines and amines as carrier ligands induce apoptosis in tumor cells resistant to cisplatin.

Structure-activity relationship of new trans-platinum(II) and (IV) complexes with cyclohexylamine. Interference with cell cycle progression and induction of cell death.

Trans-platinum(II) complexes with cyclohexylamine as expectator ligand induce necrosis in tumour cells by inhibiting DNA synthesis and RNA transcription.

High throughput screening in drug discovery.

CBX7 controls the growth of normal and tumor-derived prostate cells by repressing the Ink4a/Arf locus.

Cooperation between Cdk4 and p27kip1 in tumor development: a preclinical model to evaluate cell cycle inhibitors with therapeutic activity.

EMX homeobox genes regulate microphthalmia and alter melanocyte biology.

Glycolytic enzymes can modulate cellular life span.

Immortalization of primary human prostate epithelial cells by c-Myc.

Inhibition of phosphatidylinositol-3-kinase synergizes with gemcitabine in low-passage tumor cell lines correlating with Bax translocation to the mitochondria.

Roscovitine targets, protein kinases and pyridoxal kinase.

Transcriptional signature of Ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemo-naive patients.